Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer

Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer

Abstract Vasohibin‐1 (VASH1) is a VEGF‐inducible endothelium‐derived angiogenesis inhibitor, and vasohibin‐2 (VASH2), its homolog, exhibits proangiogenic activity. VASH2 is expressed by various cancer cells and accelerates tumor angiogenesis and progression. VASH2 was recently shown to exhibit tubul...

Full description

Bibliographic Details
Main Authors: Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Takahiro Yoshiba, Suzuyo Takahashi, Akiyo Taneichi, Yuji Takei, Masashi Urabe, Hiroaki Mizukami, Hiroyuki Fujiwara
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
CRISPR/Cas9
detyrosinated tubulin
ovarian cancer
paclitaxel
vasohibin‐2
Online Access:https://doi.org/10.1002/cam4.3841

Similar Items

Similar Items